(Q33654582)

28 July 2017

1 reference

title

Hormonal therapy for breast cancer. An update (English)

1 reference

28 July 2017

2

Jordan VC

1 reference

28 July 2017

Gradishar WJ

1

1 reference

28 July 2017

1 April 1999

1 reference

Hematology / Oncology Clinics of North America

28 July 2017

1 reference

28 July 2017

13

1 reference

28 July 2017

435-55, vii

1 reference

28 July 2017

2

1 reference

Tamoxifen and endometrial cancer: from experiment to patient.

28 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Goserelin in Premenopausal Advanced Breast Cancer: Clinical and Endocrine Evaluation of Responsive Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Goserelin depot in the treatment of premenopausal advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Treatment of pre-menopausal advanced breast cancer with goserelin--a long-acting luteinizing hormone releasing hormone agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Tumor lysis syndrome after tamoxifen flare

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Hormone-induced tumor flare

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Second generation aromatase inhibitor--4-hydroxyandrostenedione

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Anastrozole--a new generation in aromatase inhibition: clinical pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

GnRH agonists and antagonists. Current clinical status

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Anastrozole (Arimidex), a new aromatase inhibitor for advanced breast cancer: mechanism of action and role in management

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Response to third-line endocrine treatment for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Use of tamoxifen for breast cancer: twenty-eight years later

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Clinical overview of anastrozole--a new selective oral aromatase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Molecular mechanisms and future uses of antiestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

The proliferation in uterine compartments of intact rats of two different strains exposed to high doses of tamoxifen or toremifene

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

The depot GnRH analogue goserelin in the treatment of premenopausal patients with metastatic breast cancer--a 5-year experience and further endocrine therapies. Cooperative German Zoladex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Cancer statistics, 1998.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Megestrol acetate versus aminoglutethimide for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Estrogen receptor variants in clinical breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Megestrol acetate in breast cancer--a panel discussion

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Plasma concentrations of medroxyprogesterone acetate and megesterol acetate during long-term follow-up in patients treated for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Aromatase inhibitors and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Aromatase inhibitors in the treatment of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Endocrine treatment for breast cancers: biological rationale and current progress

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Fundamental research leading to improved endocrine therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Clinical importance of intratumoral aromatase

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Tamoxifen in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Five years of tamoxifen--or more?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

4-hydroxyandrostenedione--further clinical and extended endocrine observations

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Megestrol acetate: phase II study of a single daily administration in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Hormonal regulation of estradiol biosynthesis, aromatase activity, and aromatase mRNA in rat ovarian follicles and corpora lutea

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Clinical use of aromatase inhibitors: current data and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Endocrine treatment of breast cancer in women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Aminoglutethimide: review of pharmacology and clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Resistance of the ovary to blockade of aromatization with aminoglutethimide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Regulation of estrogen biosynthesis by human adipose cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Prolonged tamoxifen exposure selects a breast cancer cell clone that is stable in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Suppression of ovarian activity by Zoladex depot (ICI 118630), a long-acting luteinizing hormone releasing hormone agonist analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Tamoxifen resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Raloxifene provides an alternative for osteoporosis prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

Steroid-hormone receptors in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970064-2

7 January 2021

10.1016/S0889-8588(05)70064-2

Identifiers

DOI

1 reference

28 July 2017

1 reference

PubMed ID

10363139